Company news
Cascade Copper Corp. news in 2008
Cascade Copper Corp.'s news releases, calls and decks from 2008, newest first.
Oncothyreon announces development plans and personnel changes and updates financial guidance
December 18, 2008
Merck KGaA acquires manufacturing rights for Stimuvax from Oncothyreon
December 18, 2008
Oncothyreon reports third quarter 2008 financial results
November 6, 2008
Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
November 4, 2008
Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call
November 3, 2008
Oncothyreon to present at BIO Investor Forum 2008
October 24, 2008
Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
September 17, 2008
Oncothyreon announces prioritization plan for development programs
September 2, 2008
Oncothyreon announces public common stock offering
September 2, 2008
Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
August 20, 2008
Oncothyreon reports second quarter 2008 financial results
August 7, 2008
Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
June 17, 2008
Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
June 11, 2008
Oncothyreon announces appointments to board of directors
June 9, 2008
Stimuvax Phase 1/2 survival data support prior results
June 2, 2008
Oncothyreon to receive milestone payment
May 14, 2008
Oncothyreon Reports First Quarter 2008 Financial Results
May 7, 2008
Oncothyreon files investigational new drug application for PX-866 oncology compound
May 1, 2008
Data for Oncothyreon's PX-12 and PX-866 presented at AACR Annual Meeting
April 16, 2008
Oncothyreon's PX-478 enhances antitumor effects of radiation therapy in preclinical models of pancreatic and brain cancer
April 15, 2008
Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
April 10, 2008
Oncothyreon announces effectiveness of shelf registration statement
April 9, 2008
Oncothyreon announces issuance of patent for PX-867
March 20, 2008
Oncothyreon to present at upcoming investment conferences
March 12, 2008
Oncothyreon reports full year and fourth quarter 2007 financial results
March 10, 2008
Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
March 7, 2008
Oncothyreon's PX-478 is effective in preclinical model of human lung cancer
February 25, 2008
Oncothyreon launches new corporate website
February 5, 2008
Oncothyreon to present at BIO CEO & Investor Conference
February 4, 2008
Oncothyreon highlights corporate and clinical objectives for 2008
January 28, 2008
Oncothyreon regains compliance with NASDAQ minimum bid listing requirement
January 2, 2008